Logo image of KLRS

KALARIS THERAPEUTICS INC (KLRS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KLRS - US4829291065 - Common Stock

5.975 USD
-0.47 (-7.22%)
Last: 11/28/2025, 9:54:33 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KLRS. KLRS was compared to 533 industry peers in the Biotechnology industry. KLRS has a great financial health rating, but its profitability evaluates not so good. KLRS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KLRS had negative earnings in the past year.
KLRS had a negative operating cash flow in the past year.
KLRS had negative earnings in each of the past 5 years.
KLRS had a negative operating cash flow in each of the past 5 years.
KLRS Yearly Net Income VS EBIT VS OCF VS FCFKLRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

KLRS has a Return On Assets (-47.33%) which is in line with its industry peers.
KLRS has a Return On Equity (-82.73%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -47.33%
ROE -82.73%
ROIC N/A
ROA(3y)-70.08%
ROA(5y)-57.81%
ROE(3y)-85.85%
ROE(5y)-70.73%
ROIC(3y)N/A
ROIC(5y)N/A
KLRS Yearly ROA, ROE, ROICKLRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

KLRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLRS Yearly Profit, Operating, Gross MarginsKLRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

KLRS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, KLRS has less shares outstanding
There is no outstanding debt for KLRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KLRS Yearly Shares OutstandingKLRS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KLRS Yearly Total Debt VS Total AssetsKLRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.88, we must say that KLRS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.88, KLRS is in line with its industry, outperforming 57.04% of the companies in the same industry.
There is no outstanding debt for KLRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.88
ROIC/WACCN/A
WACCN/A
KLRS Yearly LT Debt VS Equity VS FCFKLRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 11.98 indicates that KLRS has no problem at all paying its short term obligations.
The Current ratio of KLRS (11.98) is better than 86.68% of its industry peers.
KLRS has a Quick Ratio of 11.98. This indicates that KLRS is financially healthy and has no problem in meeting its short term obligations.
KLRS has a Quick ratio of 11.98. This is amongst the best in the industry. KLRS outperforms 86.68% of its industry peers.
Industry RankSector Rank
Current Ratio 11.98
Quick Ratio 11.98
KLRS Yearly Current Assets VS Current LiabilitesKLRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.78% over the past year.
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KLRS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.68%
EPS Next 2Y37.95%
EPS Next 3Y24.59%
EPS Next 5Y14.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KLRS Yearly Revenue VS EstimatesKLRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2027 2029 2030 2031 2032 50M 100M 150M 200M
KLRS Yearly EPS VS EstimatesKLRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KLRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLRS Price Earnings VS Forward Price EarningsKLRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLRS Per share dataKLRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

KLRS's earnings are expected to grow with 24.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.95%
EPS Next 3Y24.59%

More info and screens

0

5. Dividend

5.1 Amount

KLRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALARIS THERAPEUTICS INC

NASDAQ:KLRS (11/28/2025, 9:54:33 AM)

5.975

-0.47 (-7.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-05 2026-03-05/amc
Inst Owners69.9%
Inst Owner Change-1.04%
Ins Owners5.88%
Ins Owner Change0%
Market Cap111.73M
Revenue(TTM)N/A
Net Income(TTM)-43.94M
Analysts86
Price Target17.34 (190.21%)
Short Float %2.51%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-116.9%
Min EPS beat(2)-218.79%
Max EPS beat(2)-15.01%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.87%
PT rev (3m)47.83%
EPS NQ rev (1m)0.34%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)0%
EPS NY rev (3m)5.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.1
P/tB 2.1
EV/EBITDA N/A
EPS(TTM)-38.41
EYN/A
EPS(NY)-3.72
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS2.84
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.33%
ROE -82.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.08%
ROA(5y)-57.81%
ROE(3y)-85.85%
ROE(5y)-70.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.98
Quick Ratio 11.98
Altman-Z -0.88
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y98.68%
EPS Next 2Y37.95%
EPS Next 3Y24.59%
EPS Next 5Y14.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.84%
OCF growth 3YN/A
OCF growth 5YN/A

KALARIS THERAPEUTICS INC / KLRS FAQ

What is the ChartMill fundamental rating of KALARIS THERAPEUTICS INC (KLRS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KLRS.


Can you provide the valuation status for KALARIS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to KALARIS THERAPEUTICS INC (KLRS). This can be considered as Overvalued.


What is the profitability of KLRS stock?

KALARIS THERAPEUTICS INC (KLRS) has a profitability rating of 1 / 10.


How financially healthy is KALARIS THERAPEUTICS INC?

The financial health rating of KALARIS THERAPEUTICS INC (KLRS) is 8 / 10.